Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Revenue (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Revenue for 6 consecutive years, with -$223.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Revenue fell 129197.11% year-over-year to -$223.3 million, compared with a TTM value of $6.6 million through Sep 2025, up 1248.98%, and an annual FY2024 reading of $566000.0, up 44.39% over the prior year.
  • Revenue was -$223.3 million for Q3 2025 at Ovid Therapeutics, down from $6.3 million in the prior quarter.
  • Across five years, Revenue topped out at $223.6 million in Q1 2025 and bottomed at -$223.3 million in Q3 2025.
  • Average Revenue over 5 years is $47.3 million, with a median of $171000.0 recorded in 2024.
  • Peak annual rise in Revenue hit 150981.08% in 2025, while the deepest fall reached 129197.11% in 2025.
  • Year by year, Revenue stood at $208.4 million in 2021, then grew by 6.77% to $222.5 million in 2022, then tumbled by 99.95% to $109000.0 in 2023, then crashed by 30.28% to $76000.0 in 2024, then plummeted by 293965.79% to -$223.3 million in 2025.
  • Business Quant data shows Revenue for OVID at -$223.3 million in Q3 2025, $6.3 million in Q2 2025, and $223.6 million in Q1 2025.